Testing firmanertinib vs chemo for first-line lung cancer with specific EGFR mutations
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial compares a new targeted therapy pill (firmanertinib) to standard chemotherapy in people with advanced non-small cell lung cancer whose tumors have a specific EGFR mutation (PACC or L861Q). If you haven't had treatment for advanced disease and your cancer matches these mutations, this study may offer a more convenient oral option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have advanced non-squamous non-small cell lung cancer (Stage IIIB/IV) that cannot be cured with surgery or standard radiation.
- Your tumor must have an EGFR PACC or L861Q mutation, confirmed by a central lab using a recent tissue or blood sample.
- You cannot have had any prior chemotherapy, targeted therapy, or immunotherapy for advanced lung cancer, though prior treatment for earlier-stage disease is okay if completed at least 12 months ago.
- You must be in good physical condition (able to perform daily activities with little difficulty) and have adequate organ function.
- You must not have certain other genetic mutations (like ALK, ROS1, RET, NTRK, BRAF V600E, or MET exon 14 skipping) that already have approved targeted treatments.
- You must not have active interstitial lung disease, uncontrolled infections, or significant heart or digestive problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining an EGFR-targeted pill with chemotherapy before surgery can shrink or control early-stage non-small cell lung cancer that has an EGFR mutation. It aims to improve outcomes for patients whose tumors can be removed surgically.
This trial tests if Firmonertinib, a targeted pill, can prevent lung cancer from returning after surgery in people with non-small cell lung cancer that has certain uncommon EGFR gene changes. If you have had complete tumor removal and have one of these specific mutations, this study may help you stay cancer-free longer.
This trial tests a combination of two targeted drugs (firmonertinib and bevacizumab) given before surgery for people with early-stage, EGFR-mutated lung cancer. The goal is to shrink the tumor and improve the chances of successful surgery.
This trial compares two targeted therapy pills, aumolertinib and osimertinib, for people with a specific EGFR mutation in advanced non-small-cell lung cancer that has spread. Both drugs are designed to block cancer growth signals. The study aims to see which one works better as a first treatment.
This study tests an oral targeted therapy (firmonertinib) as the first treatment for advanced EGFR-mutated non-small cell lung cancer. It uses blood tests (ctDNA) to see if the drug is working and to guide whether to continue or adjust treatment, aiming to improve outcomes while reducing side effects.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
Hear when a new EGFR trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.